Monitor the company's updated development plan for NEO212, which will detail the costs and timelines for the capsule-to-tablet transition and CMC work. The FDA's constructive feedback reduces near-term regulatory risk but does not alter the clinical-stage profile. Look for subsequent announcements on clinical trial progress or financing needs.
Price Chart
Executive Summary
NeOnc Technologies received written FDA feedback on the CMC development program for NEO212, its temozolomide-perillyl alcohol conjugate. The FDA provided constructive guidance on manufacturing and formulation requirements, including the need for an in vivo bioavailability study to support a capsule-to-tablet transition. The company canceled the scheduled Type B End-of-Phase 1 meeting, deeming the written responses sufficient, and will provide an updated development plan after assessing the requirements.
Key Facts
- FDA written feedback provided on CMC development for NEO212
- FDA stated proposed CMC approach appears reasonable
- Capsule-to-tablet transition requires in vivo relative bioavailability study
- Additional CMC work needed before using tablet in confirmatory trials: finalize formulation, GMP batch, in-process controls, characterization, dissolution method
- Company canceled July 9, 2026 Type B End-of-Phase 1 meeting after reviewing feedback
- Company expects to issue an updated development plan after evaluating timelines and costs
Financial Impact
No financial impact quantified; regulatory development milestone with no revenue implications
Risk Factors
- Regulatory risk: FDA may require additional studies or data beyond current feedback
- Execution risk: CMC activities and bioavailability study could delay late-stage clinical program
- Funding risk: no disclosed capital; development costs may require future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-007585 |
| Document: neonctechnologies_ex99-1.htm | 0001829126-26-007585 |
| Document: 0001829126-26-007585-index-headers.html | 0001829126-26-007585 |
| Document: 0001829126-26-007585-index.html | 0001829126-26-007585 |
| Document: 0001829126-26-007585.txt | 0001829126-26-007585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $2.95 | awaiting T+60 | — | $3.24 (+9.83%) |
Oct 15, 2026 10d ago | 8-K | $2.70 | awaiting T+60 | — | $3.24 (+20.00%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $3.24 (−2.70%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $3.24 (−4.99%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $3.24 (+8.36%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $3.24 (+11.48%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $3.24 (+11.48%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $3.24 (−30.70%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $3.24 (−41.41%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $3.24 (−6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers